Stocktoria
Replimune Group, Inc. REPL
Nasdaq · XNAS · stock · Biological Products, (No Diagnostic Substances) · website · IPO 2018-07-20
Replimune Group, Inc. financials (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| R&D expense | $189.4M | $175.0M | $126.5M | $79.5M | $56.8M |
| Operating income | -$261.6M | -$234.8M | -$177.1M | -$118.3M | -$80.0M |
| Income tax | $468,000 | $408,000 | $288,000 | $0 | $0 |
| Net income | -$247.3M | -$215.8M | -$174.3M | -$118.0M | -$80.9M |
| EPS (diluted) | $-3.07 | $-3.24 | $-2.99 | $-2.26 | $-1.75 |
| Operating cash flow | -$192.2M | -$185.5M | -$128.1M | -$82.2M | -$61.4M |
| Free cash flow | — | — | -$130.3M | -$84.5M | -$63.8M |
| Cash & equivalents | $111.1M | $74.5M | $146.6M | $105.9M | $182.5M |
| Total assets | $551.3M | $487.7M | $646.6M | $461.2M | $543.1M |
| Total liabilities | $135.5M | $113.2M | $91.3M | $50.0M | $44.4M |
| Shareholders' equity | $415.8M | $374.5M | $555.3M | $411.2M | $498.7M |
Source: SEC EDGAR filings · CIK 0001737953 · as of 2025-03-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.